SGLT2 inhibitors such as DN and dipeptidyl peptidase-4 (DPP-4) inhibitors like SN is potentially beneficial in achieving glycemic control without the risk of hypoglycemia or weight gain treatment of type 2 diabetes (Santos et al., 2017). Here, SLC5A2 is linked to type 2 diabetes mellitus.